These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 14744949)
1. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Wang YH; Jones DR; Hall SD Drug Metab Dispos; 2004 Feb; 32(2):259-66. PubMed ID: 14744949 [TBL] [Abstract][Full Text] [Related]
2. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Wang YH; Jones DR; Hall SD Drug Metab Dispos; 2005 May; 33(5):664-71. PubMed ID: 15689501 [TBL] [Abstract][Full Text] [Related]
3. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. Wang J; Xia S; Xue W; Wang D; Sai Y; Liu L; Liu X Eur J Pharm Sci; 2013 Nov; 50(3-4):290-302. PubMed ID: 23916407 [TBL] [Abstract][Full Text] [Related]
4. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As. Shen L; Fitzloff JF; Cook CS Drug Metab Dispos; 2004 Feb; 32(2):186-96. PubMed ID: 14744940 [TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Tracy TS; Korzekwa KR; Gonzalez FJ; Wainer IW Br J Clin Pharmacol; 1999 May; 47(5):545-52. PubMed ID: 10336579 [TBL] [Abstract][Full Text] [Related]
6. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. Kim HJ; Choi JS Biopharm Drug Dispos; 2005 Oct; 26(7):295-300. PubMed ID: 16013069 [TBL] [Abstract][Full Text] [Related]
7. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. Hu N; Xie S; Liu L; Wang X; Pan X; Chen G; Zhang L; Liu H; Liu X; Liu X; Xie L; Wang G Drug Metab Dispos; 2011 Mar; 39(3):419-25. PubMed ID: 21135265 [TBL] [Abstract][Full Text] [Related]
8. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Ma B; Prueksaritanont T; Lin JH Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508 [TBL] [Abstract][Full Text] [Related]
9. Influence of Amlodipine Enantiomers on Human Microsomal Cytochromes P450: Stereoselective Time-Dependent Inhibition of CYP3A Enzyme Activity. Krasulova K; Holas O; Anzenbacher P Molecules; 2017 Nov; 22(11):. PubMed ID: 29099769 [TBL] [Abstract][Full Text] [Related]
10. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446 [TBL] [Abstract][Full Text] [Related]
11. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin. Hong SP; Chang KS; Koh YY; Choi DH; Choi JS Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809 [TBL] [Abstract][Full Text] [Related]
12. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. Choi DH; Shin WG; Choi JS Eur J Clin Pharmacol; 2008 May; 64(5):445-9. PubMed ID: 18193210 [TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Yeo KR; Yeo WW Br J Clin Pharmacol; 2001 May; 51(5):461-70. PubMed ID: 11422004 [TBL] [Abstract][Full Text] [Related]
14. Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats. Xie SS; Hu N; Jing XY; Liu XD; Xie L; Wang GJ; Liu CH J Pharm Pharmacol; 2010 Apr; 62(4):440-7. PubMed ID: 20604832 [TBL] [Abstract][Full Text] [Related]
15. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity. Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571 [TBL] [Abstract][Full Text] [Related]
16. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. Sandström R; Knutson TW; Knutson L; Jansson B; Lennernäs H Br J Clin Pharmacol; 1999 Aug; 48(2):180-9. PubMed ID: 10417494 [TBL] [Abstract][Full Text] [Related]
17. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. Polasek TM; Sadagopal JS; Elliot DJ; Miners JO Eur J Clin Pharmacol; 2010 Mar; 66(3):275-83. PubMed ID: 20012430 [TBL] [Abstract][Full Text] [Related]
18. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. Choi DH; Chung JH; Choi JS Eur J Clin Pharmacol; 2010 Mar; 66(3):285-90. PubMed ID: 20012601 [TBL] [Abstract][Full Text] [Related]
20. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats. Chung JH; Choi DH; Choi JS Biopharm Drug Dispos; 2009 Mar; 30(2):90-3. PubMed ID: 19226653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]